Article ID Journal Published Year Pages File Type
6063621 Journal of Allergy and Clinical Immunology 2016 8 Pages PDF
Abstract
Benefits of omalizumab treatment were evident early (before week 4) in some patients and persisted to week 24. Use of 300 mg of omalizumab demonstrated best results in controlling CIU/CSU symptoms.
Related Topics
Life Sciences Immunology and Microbiology Immunology
Authors
, , , , , , , , , , , , , , ,